<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        422-212-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FUNGISKA 50 mg Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CASPOFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        639.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MEFAR ILAC SANAYII A.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MEFAR ILAC SANAYII A.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Fungiska is</strong><br />Fungiska contains a medicine called caspofungin. This belongs to a group of<br />medicines called antifungals.<br /><strong>What Fungiska is used for</strong><br />Fungiska is used to treat the following infections in children, adolescents and<br />adults:<br />&bull; Serious fungal infections in your tissues or organs (called &lsquo;invasive candidiasis&rsquo;). This<br />infection is caused by fungal (yeast) cells called Candida. People who might get this<br />type of infection include those who have just had an operation or those whose<br />immune systems are weak. Fever and chills that do not respond to an antibiotic are<br />the most common signs of this type of infection.<br />&bull; Fungal infections in your nose, nasal sinuses or lungs (called &lsquo;invasive aspergillosis&rsquo;) if<br />other anti-fungal treatments have not worked or have caused side effects. This<br />infection is caused by a mould called Aspergillus. People who might get this type of</p><p>infection include those having chemotherapy, those who have had a transplant and<br />those whose immune systems are weak.<br />&bull; Suspected fungal infections if you have a fever and a low white cell count that have<br />not improved on treatment with an antibiotic. People who are at risk of getting a<br />fungal infection include those who have just had an operation or those whose immune<br />systems are weak.</p><p><br /><strong>How Fungiska works</strong><br />Fungiska makes fungal cells fragile and stops the fungus from growing properly.<br />This stops the infection from spreading and gives the body&rsquo;s natural defenses a<br />chance to completely get rid of the infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Fungiska</strong><br />&bull; if you are allergic to caspofungin or any of the other ingredients of this medicine<br />(listed in section 6).<br />If you are not sure, talk to your doctor, nurse or pharmacist before you are<br />given your medicine.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor, nurse or pharmacist before you are given Fungiska:<br />&bull; if you are allergic to any other medicines.<br />&bull; if you have ever had liver problems - you might need a different dose of this medicine.<br />&bull; if you are already taking cyclosporin (used to help prevent organ transplant rejection<br />or to<br />suppress your immune system) - as your doctor may need to run extra blood tests<br />during your treatment.<br />&bull; if you have ever had any other medical problem.<br />Fungiska may also cause Serious Cutaneous Adverse Reactions such as<br />Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).<br />If any of the above applies to you (or you are not sure), talk to your doctor,<br />nurse or pharmacist before you are given Fungiska.<br /><strong>Children and adolescents</strong><br />Fungiska can be used in patients of 12 months to 17 years of age.</p><p><strong>Other medicines and Fungiska</strong><br />Tell your doctor, nurse or pharmacist if you are taking, have recently taken or<br />might take any other medicines. This includes medicines obtained without a<br />prescription, including herbal medicines. This is because Fungiska can affect<br />the way some other medicines work. Also some other medicines can affect<br />the way Fungiska works.<br />Tell your doctor, nurse or pharmacist if you are taking any of the following<br />medicines:<br />&bull; cyclosporin or tacrolimus (used to help prevent organ transplant rejection or to<br />suppress your immune system) as your doctor may need to run extra blood tests<br />during your treatment;<br />&bull; some HIV medicines such as efavirenz or nevirapine;<br />&bull; phenytoin or carbamazepine (used for the treatment of seizures);<br />&bull; dexamethasone (a steroid);<br />&bull; rifampicin (an antibiotic).<br />If any of the above apply to you (or you are not sure), talk to your doctor,<br />nurse or pharmacist before you are given Fungiska.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor, nurse or pharmacist for advice<br />before using this medicine.<br />&bull; Fungiska has not been studied in pregnant women. It should be used in pregnancy<br />only if the potential benefit justifies the potential risk to the unborn baby.<br />&bull; Women given Fungiska should not breast-feed.<br /><strong>Driving and using machines</strong><br />There is no information to suggest that Fungiska affects your ability to drive or<br />operate machinery.<br /><strong>Fungiska contains sucrose</strong><br />Sucrose is a type of sugar. If you have been told by your doctor that you<br />cannot tolerate or digest some sugars, talk to your doctor, nurse or pharmacist<br />before you are given this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fungiska will always be prepared and given to you by a healthcare<br />professional.</p><p>You will be given Fungiska:<br />&bull; once each day.<br />&bull; by slow injection into a vein (intravenous infusion).<br />&bull; over about 1 hour.<br />Your doctor will determine the duration of your treatment and how much<br />Fungiska you will be given each day. Your doctor will monitor how well the<br />medicine works for you. If you weigh more than 80 kg, you may need a<br />different dose.<br /><strong>Use in children and adolescents</strong><br />The dose for children and adolescents may differ from the adult dose.<br /><strong>If you have been given more Fungiska than you should</strong><br />Your doctor will decide how much Fungiska you need and for how long each<br />day. If you are worried that you may have been given too much Fungiska, tell<br />your doctor or nurse straight away.<br />If you have any further questions on the use of this medicine, ask your doctor,<br />nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br /><strong>Tell your doctor or nurse straight away if you notice any of the following side<br />effects as you may need urgent medical treatment:</strong><br />&bull; rash, itching, feeling warm, swelling of your face, lips or throat or difficulty breathing -<br />you may be having a histamine reaction to the medicine;<br />&bull; difficulty breathing with wheezing or a rash that gets worse - you may be having an<br />allergic reaction to the medicine;<br />&bull; cough, serious breathing difficulties - if you are an adult and have invasive aspergillosis<br />you may be experiencing a serious respiratory problem that could result in respiratory<br />failure.<br />As with any prescription medicine, some side effects may be serious. Ask your<br />doctor for more information.<br />Other side effects in adults include:<br />Common (may affect up to 1 in 10 people):<br />&bull; decreased haemoglobin (decreased oxygen carrying substance in the blood), decreased<br />white blood cells;</p><p>&bull; decreased blood albumin (a type of protein) in your blood, decreased potassium or low<br />potassium levels in the blood;<br />&bull; headache;<br />&bull; inflammation of the vein;<br />&bull; shortness of breath;<br />&bull; diarrhoea, nausea or vomiting;<br />&bull; changes in some laboratory blood tests (including increased values of some liver tests);<br />&bull; itching, rash, skin redness or sweating more than usual;<br />&bull; joint pain;<br />&bull; chills, fever;<br />&bull; itching at the injection site.</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):<br />&bull; changes in some laboratory blood tests (including disease of blood clotting, platelets, red<br />blood cells and white blood cells);<br />&bull; loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar<br />level in the blood, low calcium level in the blood, low magnesium level in the blood,<br />increase in acid level in the blood;<br />&bull; disorientation, feeling nervous, being unable to sleep;<br />&bull; feeling dizzy, decreased feeling or sensitivity (especially in the skin), shaking, feeling<br />sleepy, change in the way things taste, tingling or numbness;<br />&bull; blurred vision, increase in tears, swollen eyelid, yellowing of the whites of the eyes;<br />&bull; sensation of fast or irregular heartbeats, rapid heartbeat, irregular heartbeat, abnormal<br />heart rhythm, heart failure;<br />&bull; flushing, hot flush, high blood pressure, low blood pressure, redness along a vein which is<br />extremely tender when touched;<br />&bull; tightening of the bands of muscle around the airways resulting in wheezing or coughing,<br />fast breathing rate, shortness of breath that wakes you up, shortage of oxygen in the<br />blood, abnormal breath sounds, crackling sounds in the lungs, wheezing, nasal congestion,<br />cough, throat pain;<br />&bull; belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth,<br />indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the<br />belly;<br />&bull; decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, liver<br />injury caused by a drug or chemical, liver disorder;<br />&bull; abnormal skin tissue, generalized itching, hives, rash of varying appearance, abnormal<br />skin, red often itchy spots on your arms and legs and sometimes on the face and the rest<br />of the body;<br />&bull; back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness;<br />&bull; loss of kidney function, sudden loss of kidney function;<br />&bull; catheter site pain, injection site complaints (redness, hard lump, pain, swelling, irritation,<br />rash, hives, leaking of fluid from the catheter into the tissue), inflammation of vein at<br />injection site;</p><p>&bull; increased blood pressure and alterations in some laboratory blood tests (including kidney<br />electrolyte and clotting tests), increased levels of the medicines you are taking that<br />weaken the immune system;<br />&bull; chest discomfort, chest pain, feeling of body temperature change, generally feeling<br />unwell, general pain, swelling of the face, swelling of the ankles, hands or feet, swelling,<br />tenderness, feeling tired.</p><p><strong>Additional side effects in children and adolescents<br />Very common </strong>(may affect more than 1 in 10 people):<br />&bull; fever.<br /><strong>Common</strong> (may affect up to 1 in 10 people):<br />&bull; headache;<br />&bull; fast heart beat;<br />&bull; flushing, low blood pressure;<br />&bull; changes in some laboratory blood tests (increased values of some liver tests);<br />&bull; itching, rash;<br />&bull; catheter site pain;<br />&bull; chills;<br />&bull; changes in some laboratory blood tests.<br /><strong>Not known</strong> (frequency cannot be estimated):<br />&bull; liver problems;<br />&bull; swelling of the ankles, hands or feet;<br />&bull; increased calcium levels in the blood have been reported.</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible<br />side effects not listed in this leaflet. By reporting side effects you can help provide more<br />information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.<br />- Do not use this medicine after the expiry date which is stated on the<br />carton and the vial after EXP. The expiry date refers to the last day of<br />that month.<br />- Store in a refrigerator at 2&deg;C to 8&deg;C.<br />- Once Fungiska has been prepared, it should be used straight away. This is<br />because it does not contain any ingredients to stop the growth of</p><p>bacteria. Only a trained healthcare professional who has read the<br />complete directions should prepare the medicine.<br />- Do not throw away any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is caspofungin. Each vial of Fungiska 50mg, 70 mg contains 50 mg, 70<br />mg of caspofungin respectively.<br />- The other ingredients are sucrose, mannitol, glacial acetic acid, sodium hydroxide and<br />water for injection (please see section 2. What you need to know before you are given<br />Fungiska).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fungiska is a sterile, white to off-white compact powder.
Each pack contains one vial of powder.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by<br />MEFAR İLA&Ccedil; SANAYİİ A.Ş. Turkey<br />For<br />SPIMACO</strong><br />Al-Qassim Pharmaceutical Plant<br />Saudi Pharmaceutical Industries &amp;<br />Medical Appliances Corporation<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو فنجسكا</strong><br />يحتوي فنجسكا على دواء يسمى كاسبوفنجن. ينتمي هذا الدواء إلى مجموعة من الأدوية تسمى مضادات الفطريات.<br /><strong>فيم يستخدم فنجسكا</strong><br />يستخدم فنجسكا لعلاج الالتهابات التالية في الأطفال والمراهقين والبالغين:<br />&bull; الالتهابات الفطرية الخطيرة في الأنسجة أو الأجهزة الخاصة بك (وتسمى &quot;المبيضات<br />الغازية&quot;). ويتسبب هذا المرض عن طريق خلايا فطرية (الخميرة) تسمى المبيضات. مجموعة<br />الأشخاص الذين قد يظهر عليهم هذا النوع من العدوى تشمل أولئك الذين خضعوا<br />لإجراء عملية أو أولئك الذين يعانون من ضعف جهاز المناعة. الحمى والقشعريرة التي لا تستجيب للمضادات الحيوية هي ال<br />علامات الأكثر شيوعا لهذا النوع من العدوى.<br />&bull; الالتهابات الفطرية في الأنف، الجيوب الأنفية أو الرئتين (وتسمى &quot;داء الرشاشيات الغازية &#39;) إذا لم<br />تنجح غيرها من العلاجات المضادة للفطريات أو قد تسببت في<br />ظهور آثار جانبية. ويتسبب هذا المرض عن طريق عفن يسمى الرشاشيات. مجموعة الأشخاص الذين قد يظهر<br />عليهم هذا النوع من العدوى تشمل من<br />يخضعون للعلاج الكيميائي، أولئك الذين خضعوا لعملية زرع أعضاء وأولئك الذين يعانون من ضعف جهاز المناعة.<br />&bull; الالتهابات الفطرية المشتبه<br />بها إذا كانت لديك حمى وعدد الخلايا البيضاء منخفض والتي لم تتحسن على العلاج بالمضادات الحيوية. مجموعة الأشخاص<br />الذين هم عرضة للإصابة بالعدوى الفطرية وتشمل أولئك الذين خضعوا<br />لإجراء عملية أو أولئك الذين يعانون من ضعف جهاز المناعة.</p><p><strong>كيف يعمل فنجسكا</strong><br />يجعل فنجسكا الخلايا الفطرية هشة ويقوم بإيقاف الفطريات عن النمو بشكل صحيح. يمنع<br />هذا انتشار العدوى ويعطي الدفاعات الطبيعية للجسم فرصة للتخلص تماما من العدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا يجب إعطاؤك فنجسكا فى الحالات الآتية:</strong><br />.( &bull; إذا كنت تعاني من حساسية ل كاسبوفنجن أو أي من المكونات الأخرى من هذا الدواء (المذكورة في الفقرة 6<br />إذا لم تكن متأكدا، قم بالتحدث مع طبيبك أو الممرضة أو الصيدلي قبل أن يتم إعطاؤك الدواء.<br /><strong>التحذيرات والاحتياطات</strong><br />اخبر طبيبك أو الممرضة أو الصيدلي قبل أن يتم إعطاؤك فنجسكا:<br />&bull; إذا كنت تعاني من حساسية لأي أدوية أخرى.<br />&bull; إذا كانت لديك في أي وقت مضى مشاكل في الكبد - قد تحتاج الى جرعة مختلفة من هذا الدواء.<br />&bull; إذا كنت تتناول بالفعل السيكلوسبورين (يستخدم للمساعدة في منع رفض زراعة الأعضاء أو لقمع نظام المناعة الخا<br />ص بك) &ndash; لذا قد يحتاج طبيبك إلى إجراء اختبارات دم إضافية أثناء العلاج.<br />&bull; إذا كانت لديك أي وقت مضى أي مشكلة طبية أخرى.<br />قد تسبب فنجيسكا أيضا ردود فعل جلدية سلبية خطيرة مثل متلازمة ستيفنز جونسون وانحلال البشرة السامة .<br />إذا كان أي من المذكور أعلاه ينطبق عليك (أو لم تكن متأكدا)، قم<br />بالتحدث مع طبيبك أو الممرضة أو الصيدلي قبل أن يتم إعطاؤك فنجسكا.<br /><strong>الأطفال والمراهقين</strong><br />يمكن استخدام فنجسكا في المرضى من عمر 12 شهرا إلى 17 سنة.<br /><strong>تناول أدوية أخري</strong><br />أخبر طبيبك أو الممرضة أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. وهذا يشمل الأدوية ال<br />تي تم الحصول عليها دون وصفة طبية، بما في ذلك الأدوية العشبية. وذلك لأن فنجسكا يمكن أن يؤثر على الطريقة التي تعم<br />ل بها بعض الأدوية الأخرى. أيضا بعض الأدوية الأخرى يمكن أن تؤثر على الطريقة التي يعمل فنجسكا.<br />أخبر طبيبك أو الممرضة أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:<br />&bull; السيكلوسبورين أو تاكروليموس (تستخدم للمساعدة في منع رفض زرع الأعضاء أو لقمع نظام المناعة الخاص بك)، والطب<br />يب قد يحتاج إلى إجراء اختبارات دم إضافية أثناء العلاج.<br />&bull; بعض أدوية فيروس نقص المناعة البشرية مثل ايفافيرنز أو نيفيرابين.<br />&bull; الفينيتوين أو كاربامازيبين (التي تستخدم لعلاج النوبات)؛<br />&bull; ديكساميثازون (الستيرويد)؛<br />&bull; ريفام ي بسين (مضاد حيوي).<br />إذا كان أي من أعلاه ينطبق عليك (أو لم تكن متأكدا)، قم بالتحدث مع طبيبك أو الممرضة أو الصيدلي قبل أن يتم إعطاؤك<br />فنجسكا.</p><p><strong>الحمل والرضاعة</strong><br />إذا كنتي حاملا أو تقومين<br />بالرضاعة الطبيعية، تعتقدين أنك قد تكون حاملا أو تخططين لإنجاب طفل، اسألي طبيبك أو الممرضة أو الصيدلي للحصول<br />على المشورة قبل استخدام هذا الدواء.<br />&bull; لم يتم دراسة<br />فنجسكا في النساء الحوامل. ينبغي استخدامه في فترة الحمل فقط إذا كانت الفائدة المرجوة تبرر الخطر المحتمل على الجنين.<br />&bull; النساء اللواتي يتم إعطاؤهن فنجسكا لا يجب عليهن القيام بالرضاعة الطبيعية.<br /><strong>القيادة واستخدام الآلات</strong><br />ليس هناك معلومات تشير إلى أن فنجسكا يؤثر على قدرتك على القيادة أو تشغيل الآلات.</p><p><strong>فنجسكا يحتوي على السكروز</strong><br />السكروز هو نوع من السكر. إذا أخبرك طبيبك من قبل أنه لا يمكنك تحمل أو هضم بعض السكريات، قم<br />بالتحدث مع طبيبك أو الممرضة أو الصيدلي قبل أن يتم منحك هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف تحضر وتعطي فنجسكا من قبل طبيب مختص دائما.<br />سوف يتم إعطاؤك فنجسكا:<br />&bull; مرة واحدة كل يوم.<br />&bull; عن طريق الحقن البطيء في الوريد (التسريب في الوريد).<br />&bull; على مدى حوالي ساعة واحدة.<br />سوف يقوم طبيبك بتحديد مدة العلاج الخاصة بك، وكمية فنجسكا التي سوف يقوم بإعطائك اياها كل يوم. سوف يقوم طبيبك<br />بمراقبة مدي ملاءمة الدواء معك. إذا كنت تزن أكثر من 80 كجم، قد تحتاج إلى جرعة مختلفة.<br /><strong>الإستخدام في الأطفال والمراهقين</strong><br />الجرعة للأطفال والمراهقين قد تختلف عن جرعة الكبار.<br /><strong>إذا تناولت فنجسكا أكثر مما يجب</strong><br />سوف يقرر الطبيب كمية فنجسكا التي تحتاج إليها ومدة العلاج. إذا كنت قلقا أنه قد تم إعطاؤك جرعة<br />مفرطة ، أخبر طبيبك أو الممرضة على الفور.<br />إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء، ا أ سل طبيبك أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، على الرغم من أنها لا تظهر علي جميع المرضي.<br /><strong>أخبر طبيبك أو الممرضة فورا إذا لاحظت أي من الآثار الجانبية التالية لأنك قد تحتاج إلى علاج طبي عاجل:</strong><br />&bull; الطفح الجلدي، والحكة، وشعورك بأنك دافئ، تورم وجهك، والشفتين أو الحلق أو صعوبة في التنفس -<br />قد يكون لديك رد فعل هستاميني للدواء.<br />&bull; صعوبة في التنفس مع صفير أو طفح والذي قد يصبح أسوأ - قد يكون لديك رد فعل تحسسي للدواء.<br />&bull; السعال وصعوبات خطيرة في التنفس - إذا كنت راشدا ولديك<br />اصابة بالرشاشيات الغازية قد تعاني من مشكلة خطيرة في الجهاز التنفسي والتي قد تؤدي إلى فشل الجهاز التنفسي.<br />كما هو الحال مع أي دواء بوصفة طبية، قد تكون بعض الآثار الجانب ة ي خطيرة. اسأل طبيبك للمزيد من المعلومات.<br />الآثار الجانبية الأخرى في البالغين تتضمن:<br /><strong>شائعة</strong> (قد يؤثر على ما يصل إلى 1 في 10 أشخاص):<br />&bull; انخفاض الهيموجلوبين (نقص المادة التي تحمل الأكسجين في الدم)، وانخفاض خلايا الدم البيضاء.<br />&bull; انخفاض الألبيومين في الدم (وهو نوع من البروتين) في الدم، وانخفاض نسبة البوتاسيوم أو انخفاض مستويات البوتاسيوم في&nbsp;الدم.<br />&bull; صداع الراس<br />&bull; التهاب الوريد؛<br />&bull; ضيق تنفس؛<br />&bull; الإسهال، والغثيان أو القيء.<br />&bull; تغييرات في بعض اختبارات الدم المخبرية (بما في ذلك زيادة نتائج بعض اختبارات الكبد)؛<br />&bull; الحكة، الطفح الجلدي، احمرار الجلد أو التعرق أكثر من المعتاد.<br />&bull; آلام المفاصل؛<br />&bull; قشعريرة، حمى؛</p><p>&bull; حكة في موقع الحقن.<br /><strong>غير الشائعة</strong> (قد يؤثر على ما يصل إلى 1 في 100 شخص):<br />&bull; تغييرات في بعض اختبارات الدم المخبرية (بما في ذلك مرض تخثر الدم، الصفائح الدموية وخلايا الدم الحمراء وخلايا الد<br />م البيضاء)؛<br />&bull; فقدان الشهية، وزيادة في كمية السوائل في الجسم، وعدم توازن الملح في الجسم، وارتفاع مستوى السكر في الدم، وانخفا<br />ض مستوى الكالسيوم في الدم، وانخفاض مستوى الماغنيسيوم في الدم، وزيادة في مستوى الحمض في الدم.<br />&bull; الارتباك، والشعور بالتوتر، عدم القدرة على النوم.<br />&bull; الشعور بالدوار، وانخفاض الشعور أو الحساسية (وخصوصا في الجلد)، والإهتزاز، والشعور بالنعاس، وتغير في مذاق<br />الأشياء، وخز أو خدر.<br />&bull; عدم وضوح الرؤية، وزيادة في الدموع، وتورم الجفن، اصفرار بياض العينين.<br />&bull; الإحساس بسرعة النبض أو عدم<br />انتظامه، سرعة ضربات القلب، عدم انتظام ضربات القلب، إيقاع القلب غير طبيعي، وفشل القلب.<br />&bull; احمرار وتوهج ساخن، وارتفاع ضغط الدم، وانخفاض ضغط الدم، احمرار على طول الوريد والذي يصبح حساسا<br />عند لمسه.<br />&bull; شد في حزمة العضلات حول الشعب الهوائية مما يؤدي إلى صوت<br />الصفير أو السعال، وسرعة معدل التنفس، وضيق في التنفس قد يؤدي إلي إيقاظك من<br />النوم، ونقص الأوكسجين في الدم، أصوات تنفس غير طبيعية، صوت طقطقة في الرئتين، والصفير، واحتقان الانف، السعال<br />، وألم في الحلق.<br />&bull; ألم في البطن، ألم في الجزء العلوي<br />من البطن، والإنتفاخ والإمساك، وصعوبة في البلع، جفاف الفم، وعسر الهضم والغازات<br />المفرطة، والمغص، وتورم بسبب تراكم السوائل حول البطن.<br />&bull; انخفاض تدفق العصارة الصفراوية، تضخم الكبد، اصفرار الجلد و / أو بياض العين، وإصابة الكبد الناجم عن الدواء أو<br />المواد الكيماوية، واضطرا ا بت الكبد.<br />&bull; أنسجة جلد غير طبيعية، وحكة عامة، والشري، وطفح جلدي متفاوت في المظهر، وجلد غير طبيعي، بقع حمراء غالبا ما ت<br />ثير الحكة في الذراعين والساقين وأحيانا على الوجه وباقي الجسم.<br />&bull; آلام الظهر، آلام في الذراع أو الساق، وآلام العظام، وآلام في العضلات، وضعف العضلات.<br />&bull; فقدان وظائف الكلى، والفقدان المفاجئ لوظائف الكلى.<br />&bull; ألم في موقع القسطرة وشكاوى في موقع الحقن (احمرار، نتوء<br />شديد، ألم، وتورم، تهيج، وطفح جلدي، والشري، تسرب السوائل من القسطرة إلي الأنسجة)، والتهاب الوريد في موقع الحقن<br />.<br />&bull; ارتفاع ضغط الدم والتعديلات في بعض اختبارات الدم المخبرية (بما في ذلك أملاح الكلى واختبارات التخثر)، وزيادة مست<br />ويات الأدوية التي تتناولها والتي تضعف الجهاز المناعي؛<br />&bull; عدم الراحة في الصدر، ألم في الصدر، الشعور بتغير في درجة حرارة الجسم، والشعور بتوعك بشكل<br />عام، والألم العام، وتورم في الوجه وتورم الكاحلين واليدين أو القدمين، تورم، والتحسس، والشعور بالتعب.<br /><strong>آثار جانبية إضافية في الأطفال والمراهقين<br />شائعة جدا</strong> (قد تؤثر على أكثر من 1 في 10 أشخاص):<br />&bull; الحمى.<br /><strong>شائعة</strong> (قد تؤثر على ما يصل إلى 1 في 10 أشخاص):<br />&bull; صداع الرأس؛<br />&bull; ضربات القلب السريعة؛<br />&bull; الإحمرار، وانخفاض ضغط الدم،<br />&bull; تغييرات في بعض اختبارات الدم المخبرية (زيادة نتائج بعض اختبارات الكبد)؛<br />&bull; الحكة والطفح الجلدي.<br />&bull; ألم في الموقع القسطرة.<br />&bull; قشعريرة.</p><p>&bull; تغييرات في نتائج بعض اختبارات الدم المخبرية.<br /><strong>غير معروفة</strong> (لا يمكن توقع معدلها):<br />&bull; مشاكل في الكبد.<br />&bull; تورم الكاحلين واليدين أو القدمين.<br />&bull; تم الإبلاغ عن زيادة مستويات الكالسيوم في الدم.<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا ظهرت<br />عليك أي آثار جانبية، تحدث مع طبيبك أو الممرضة أو الصيدلي. ويشمل ذلك أي آثار جانبية محتملة غير مذكورة في هذه الن<br />شرة. من خلال الإبلاغ عن الآثار الجانبية يمكن أن تساعد على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ هذا الدواء بعيدا عن بصر ومتناول الأطفال.<br />تاريخ انتهاء الص .EXP &bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الذي ورد على الكرتون والقارورة بعد<br />لاحية يشير إلى اليوم الأخير من ذلك الشهر.<br />&bull; يحفظ في الثلاجة في درجة حرارة من 2 درجة مئوية إلى 8 درجات مئوية.<br />&bull; بمجرد تحضير<br />فنجسكا، ينبغي استخدامه على الفور. وهذا لأنه لا يحتوي على أي مكونات لوقف نمو البكتيريا. الطبيب المختصالمدرب<br />الذي قام بقراءة الإرشادات كاملة فقط هو من يجب عليه تحضير الدواء.<br />&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص<br />من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير علي حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة هي كاسبوفنجن. كل قارورة من فنجسكا 50<br />ملجم، 70 ملجم تحتوي على 50 ملجم، 70 ملجم من كاسبوفنجن على التوالي.<br />-<br />المكونات الأخرى هي السكروز، مانيتول، حمض الخليك الجليدي، وهيدروكسيد الصوديوم وماء للحقن (انظر الفقرة 2. ما<br />تحتاج إلى معرفته قبل أن يتم إعطاؤك فنجسكا).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">فنجسكا مسحوق مضغوط معقم، أبيض إلي أبيض مطفي.<br />كل علبة تحتوي على قارورة واحدة من المسحوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج:<br />إم إيه إف الصيدلانية - تركيا<br />لصالح:<br />الدوائية<br />مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشرة بتاريخ مارس 2017 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fungiska 50 mg powder for concentrate for solution for infusion
Fungiska70 mg powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 50 mg vial contains 50 mg caspofungin (as acetate).
Each 70 mg vial contains 70 mg caspofungin (as acetate).
Excipients with known effect:
Each 50 mg vial contains 35.7 mg of sucrose.
Each 70 mg vial contains 50.0 mg of sucrose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
Before reconstitution, the lyophilized powder is a white to off-white.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Treatment of invasive candidiasis in adult or paediatric patients.<br />&bull; Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to<br />or intolerant of amphotericin B, lipid formulations of amphotericin B and/or<br />itraconazole. Refractoriness is defined as progression of infection or failure to improve<br />after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.<br />&bull; Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in<br />febrile, neutropaenic adult or paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caspofungin should be initiated by a physician experienced in the management of invasive<br />fungal infections.<br /><u>Posology</u><br /><em>Adult patients</em><br />A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily<br />thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose,</p><p>caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary<br />based on gender or race (see section 5.2).<br /><em>Paediatric patients (12 months to 17 years)</em><br />In paediatric patients (12 months to 17 years of age), dosing should be based on the patient&#39;s<br />body surface area (see Instructions for Use in Paediatric Patients, Mosteller1 Formula). For all<br />indications, a single 70-mg/m2 loading dose (not to exceed an actual dose of 70 mg) should be<br />administered on Day 1, followed by 50 mg/m2 daily thereafter (not to exceed an actual dose of<br />70 mg daily). If the 50-mg/m2 daily dose is well tolerated but does not provide an adequate<br />clinical response, the daily dose can be increased to 70 mg/m2 daily (not to exceed an actual<br />daily dose of 70 mg).<br />The safety and efficacy of caspofungin have not been sufficiently studied in clinical trials<br />involving neonates and infants below 12 months of age. Caution is advised when treating this<br />age group. Limited data suggest that caspofungin at 25 mg/m2 daily in neonates and infants<br />(less than 3 months of age) and 50 mg/m2 daily in young children (3 to 11 months of age) can<br />be considered (see section 5.2).<br /><u>Duration of treatment</u><br />Duration of empirical therapy should be based on the patient&#39;s clinical response. Therapy<br />should be continued until up to 72 hours after resolution of neutropaenia (ANC&ge; 500). Patients<br />found to have a fungal infection should be treated for a minimum of 14 days and treatment<br />should continue for at least 7 days after both neutropaenia and clinical symptoms are resolved.<br />Duration of treatment of invasive candidiasis should be based upon the patient&#39;s clinical and<br />microbiological response. After signs and symptoms of invasive candidiasis have improved<br />and cultures have become negative, a switch to oral antifungal therapy may be considered. In<br />general, antifungal therapy should continue for at least 14 days after the last positive culture.<br />Duration of treatment of invasive aspergillosis is determined on a case by case basis and should<br />be based upon the severity of the patient&#39;s underlying disease, recovery from<br />immunosuppression, and clinical response. In general, treatment should continue for at least 7<br />days after resolution of symptoms.<br />The safety information on treatment durations longer than 4 weeks is limited. However,<br />available data suggest that caspofungin continues to be well tolerated with longer courses of<br />therapy (up to 162 days in adult patients and up to 87 days in paediatric patients).<br /><em><strong>Special populations</strong><br />Elderly patients</em><br />In elderly patients (65 years of age or more), the area under the curve (AUC) is increased by<br />approximately 30 %. However, no systematic dosage adjustment is required. There is limited<br />treatment experience in patients 65 years of age and older (see section 5.2).</p><p><em>Renal impairment</em><br />No dosage adjustment is necessary based on renal impairment (see section 5.2).<br /><em>Hepatic impairment</em><br />For adult patients with mild hepatic impairment (Child-Pugh score 5 to 6), no dosage<br />adjustment is needed. For adult patients with moderate hepatic impairment (Child-Pugh score 7<br />to 9), caspofungin 35 mg daily is recommended based upon pharmacokinetic data. An initial 70<br />mg loading dose should be administered on Day-1. There is no clinical experience in adult<br />patients with severe hepatic impairment (Child-Pugh score greater than 9) and in paediatric<br />patients with any degree of hepatic impairment (see section 4.4).<br /><u>Co-administration with inducers of metabolic enzymes</u><br />Limited data suggest that an increase in the daily dose of caspofungin to 70 mg, following the<br />70 mg loading dose, should be considered when co-administering caspofungin in adult patients<br />with certain inducers of metabolic enzymes (see section 4.5). When caspofungin is coadministered<br />to paediatric patients (12 months to 17 years of age) with these same inducers of<br />metabolic enzymes (see section 4.5), a caspofungin dose of 70-mg/m2 daily (not to exceed an<br />actual daily dose of 70 mg) should be considered.<br /><u>Method of administration</u><br />After reconstitution and dilution, the solution should be administered by slow intravenous<br />infusion over approximately 1 hour. For reconstitution directions see section 6.6.<br />Both 70 mg and 50 mg vials are available.<br />Caspofungin should be given as a single daily infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anaphylaxis has been reported during administration of caspofungin. If this occurs,<br />caspofungin should be discontinued and appropriate treatment administered. Possibly<br />histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus,<br />sensation of warmth, or bronchospasm have been reported and may require discontinuation<br />and/or administration of appropriate treatment.<br />Limited data suggest that less common non-Candida yeasts and non-Aspergillusmoulds are not<br />covered by caspofungin. The efficacy of caspofungin against these fungal pathogens has not<br />been established.<br />Concomitant use of caspofungin with ciclosporin has been evaluated in healthy adult<br />volunteers and in adult patients. Some healthy adult volunteers who received two 3 mg/kg<br />doses of ciclosporin with caspofungin showed transient increases in alanine transaminase</p><p>(ALT) and aspartate transaminase (AST) of less than or equal to 3-fold the upper limit of<br />normal (ULN) that resolved with discontinuation of the treatment. In a retrospective study of<br />40 patients treated during marketed use with caspofungin and ciclosporin for 1 to 290 days<br />(median 17.5 days), no serious hepatic adverse reactions were noted. These data suggest that<br />casopofungin can be used in patients receiving ciclosporin when the potential benefit<br />outweighs the potential risk. Close monitoring of liver enzymes should be considered if<br />caspofungin and ciclosporin are used concomitantly.<br />In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20%<br />and 75 %, respectively. A reduction of the daily dose to 35 mg is recommended for adults with<br />moderate hepatic impairment. There is no clinical experience in adults with severe hepatic<br />impairment or in paediatric patients with any degree of hepatic impairment. A higher exposure<br />than in moderate hepatic impairment is expected and caspofungin should be used with caution<br />in these patients (see sections 4.2 and 5.2).<br />Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult<br />and paediatric patients treated with caspofungin. In some adult and paediatric patients with<br />serious underlying conditions who were receiving multiple concomitant medications with<br />caspofungin, cases of clinically significant hepatic dysfunction, hepatitis and hepatic failure<br />have been reported; a causal relationship to caspofungin has not been established. Patients who<br />develop abnormal liver function tests during caspofungin therapy should be monitored for<br />evidence of worsening hepatic function and the risk/benefit of continuing caspofungin therapy<br />should be re-evaluated.<br />This medicinal product contains sucrose. Patients with rare hereditary problems of fructose<br />intolerance or sucrase-isomaltase insufficiency should not take this medicinal product (see<br />section 2).<br />Cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been<br />reported after post-marketing use of caspofungin. Caution should apply in patients with history<br />of allergic skin reaction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies in vitro show that caspofungin is not an inhibitor of any enzyme in the cytochrome<br />P450 (CYP) system. In clinical studies, caspofungin did not induce the CYP3A4 metabolism of<br />other substances. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for<br />cytochrome P450 enzymes. However, caspofungin has been shown to interact with other<br />medicinal products in pharmacological and clinical studies (see below).<br />In two clinical studies performed in healthy adult subjects, ciclosporin A (one 4 mg/kg dose or<br />two 3 mg/kg doses 12 hours apart) increased the AUC of caspofungin by approximately 35 %.<br />These AUC increases are probably due to reduced uptake of caspofungin by the liver.<br />Caspofungin did not increase the plasma levels of ciclosporin. There were transient increases in<br />liver ALT and AST of less than or equal to 3-fold the upper limit of normal (ULN) when<br />caspofungin and ciclosporin were co-administered, that resolved with discontinuation of the<br />medicinal products. In a retrospective study of 40 patients treated during marketed use with</p><p>caspofungin and ciclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse<br />reactions were noted (see section 4.4). Close monitoring of liver enzymes should be considered<br />if the two medicinal products are used concomitantly.<br />Caspofungin reduced the trough concentration of tacrolimus by 26 % in healthy adult<br />volunteers. For patients receiving both therapies, standard monitoring of tacrolimus blood<br />concentrations and appropriate tacrolimus dosage adjustments are mandatory.<br />Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are<br />not altered to a clinically relevant extent by itraconazole, amphotericin B, mycophenolate,<br />nelfinavir, or tacrolimus. Caspofungin did not influence the pharmacokinetics of amphotericin<br />B, itraconazole, rifampicin or mycophenolatemofetil. Although safety data are limited it<br />appears that no special precautions are needed when amphotericin B, itraconazole, nelfinavir or<br />mycophenolatemofetil are co-administered with caspofungin.<br />Rifampicin caused a 60 % increase in AUC and 170 % increase in trough concentration of<br />caspofungin on the first day of co-administration when both medicinal products were initiated<br />together in healthy adult volunteers. Caspofungin trough levels gradually decreased upon<br />repeated administration. After two weeks&#39; administration rifampicin had limited effect on<br />AUC, but trough levels were 30 % lower than in adult subjects who received caspofungin<br />alone. The mechanism of interaction could possibly be due to an initial inhibition and<br />subsequent induction of transport proteins. A similar effect could be expected for other<br />medicinal products that induce metabolic enzymes. Limited data from population<br />pharmacokinetics studies indicate that concomitant use of caspofungin with the inducers<br />efavirenz, nevirapine, rifampicin, dexamethasone, phenytoin, or carbamazepine may result in a<br />decrease in caspofungin AUC. When co-administering inducers of metabolic enzymes, an<br />increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should<br />be considered in adult patients (see section 4.2).<br />All adult drug-drug interaction studies described above were conducted at a 50 or 70 mg daily<br />caspofungin dose. The interaction of higher doses of caspofungin with other medicinal<br />products has not been formally studied.<br />In paediatric patients, results from regression analyses of pharmacokinetic data suggest that coadministration<br />of dexamethasone with caspofungin may result in clinically meaningful<br />reductions in caspofungin trough concentrations. This finding may indicate that paediatric<br />patients will have similar reductions with inducers as seen in adults. When caspofungin is coadministered<br />to paediatric patients (12 months to 17 years of age) with inducers of drug<br />clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or<br />carbamazepine, a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70<br />mg) should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no or limited data from the use of caspofungin in pregnant women. Caspofungin<br />should not be used during pregnancy unless clearly necessary. Animal studies have shown<br />developmental toxicity (see section 5.3). Caspofungin has been shown to cross the placental<br />barrier in animal studies.<br /><u>Breastfeeding</u><br />It is unknown whether caspofungin is excreted in human milk. Available pharmacodynamic/<br />toxicological data in animals have shown excretion of caspofungin in milk. Women receiving<br />caspofungin should not breast-feed.<br /><u>Fertility</u><br />For caspofungin, there were no effects on fertility in studies conducted in male and female rats<br />(see section 5.3). There are no clinical data for caspofungin to assess its impact on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions (anaphylaxis and possibly histamine-mediated adverse reactions)<br />have been reported (see section 4.4).<br />Also reported in patients with invasive aspergillosis were pulmonary oedema, adult respiratory<br />distress syndrome (ARDS), and radiographic infiltrates.<br /><u><em>Adult Patients</em></u><br />In clinical studies, 1,865 adult individuals received single or multiple doses of caspofungin:<br />564 febrile neutropaenic patients (empirical therapy study), 382 patients with invasive<br />candidiasis, 228 patients with invasive aspergillosis, 297 patients with localisedCandida<br />infections, and 394 individuals enrolled in Phase I studies. In the empirical therapy study<br />patients had received chemotherapy for malignancy or had undergone haematopoietic stem-cell<br />transplantation (including 39 allogeneic transplantations). In the studies involving patients with<br />documented Candida infections, the majority of the patients with invasive Candida infections<br />had serious underlying medical conditions (e.g., haematologic or other malignancy, recent<br />major surgery, HIV) requiring multiple concomitant medications. Patients in the noncomparative<br />Aspergillus study often had serious predisposing medical conditions (e.g., bone<br />marrow or peripheral stem cell transplants, haematologic malignancy, solid tumours or organ<br />transplants) requiring multiple concomitant medications.<br />Phlebitis was a commonly reported local injection-site adverse reaction in all patient<br />populations. Other local reactions included erythema, pain/tenderness, itching, discharge, and a<br />burning sensation.<br />Reported clinical and laboratory abnormalities among all adults treated with caspofungin (total<br />1,780) were typically mild and rarely led to discontinuation.</p><p>The following adverse reactions were reported:<br />[Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge;1/1,000 to &lt;1/100)]<br /><strong>Blood and lymphatic system disorders:</strong><br />Common:haemoglobin decreased, haematocrit decreased, white blood cell count decreased<br />Uncommon:anaemia, thrombocytopaenia, coagulopathy, leukopaenia, eosinophil count<br />increased, platelet count decreased, platelet count increased, lymphocyte count decreased,<br />white blood cell count increased, neutrophil count decreased<br /><strong>Metabolism and nutrition disorders:</strong><br />Common: hypokalemia<br />Uncommon: fluid overload, hypomagnesaemia, anorexia, electrolyte imbalance,<br />hyperglycaemia, hypocalcaemia, metabolic acidosis<br /><strong>Psychiatric disorders</strong><br />Uncommon: anxiety, disorientation, insomnia<br /><strong>Nervous system disorders:</strong><br />Common: headache<br />Uncommon: dizziness, dysgeusia, paraesthesia, somnolence, tremor, hypoaesthesia<br /><strong>Eye disorders:</strong><br />Uncommon: ocular icterus, vision blurred, eyelid oedema, lacrimation increased<br /><strong>Cardiac disorders:</strong><br />Uncommon: palpitations, tachycardia, arrhythmia, atrial fibrillation, cardiac failure congestive<br /><strong>Vascular disorders:</strong><br />Common: phlebitis<br />Uncommon: thrombophlebitis, flushing, hot flush, hypertension, hypotension<br /><strong>Respiratory, thoracic and mediastinal disorders:</strong><br />Common:dyspnoea<br />Uncommon: nasal congestion, pharyngolaryngeal pain, tachypnoea, bronchospasm, cough,<br />dyspnoea paroxysmal nocturnal, hypoxia, rales, wheezing<br /><strong>Gastrointestinal disorders:</strong><br />Common: nausea, diarrhoea, vomiting<br />Uncommon: abdominal pain, abdominal pain upper, dry mouth, dyspepsia, stomach<br />discomfort, abdominal distension, ascites, constipation, dysphagia, flatulence<br /><strong>Hepatobiliary disorders:</strong><br />Common: elevated liver values (alanine aminotransferase, aspartate aminotranserase, blood<br />alkaline phosphatase, bilirubin conjugated, blood bilirubin)</p><p>Unommon: cholestasis, hepatomegaly, hyperbilirubinaemia, jaundice, hepatic function<br />abnormal, hepatotoxicity, liver disorder, gamma-glutamyltransferase increased<br /><strong>Skin and subcutaneous tissue disorders:</strong><br />Common: rash, pruritus, erythema, hyperhidrosis<br />Uncommon: erythema multiforme, rash macular, rash maculo-papular, rash pruritic, urticaria,<br />dermatitis allergic, pruritus generalised, rash erythematous, rash generalised, rash morbilliform,<br />skin lesion<br />Not known (cannot be estimated from available data): Toxic epidermal necrolysis and Stevens-<br />Johnson syndrome<br /><strong>Musculoskeletal and connective tissue disorders</strong><br />Common: arthralgia<br />Uncommon: back pain, pain in extremity, bone pain, muscular weakness, myalgia<br /><strong>Renal and urinary disorders</strong><br />Uncommon: renal failure, renal failure acute<br /><strong>General disorders and administration site conditions:</strong><br />Common: pyrexia, chills, infusion-site pruritus<br />Uncommon: pain, catheter site pain, fatigue, feeling cold, feeling hot, infusion site erythema,<br />infusion site induration, infusion site pain, infusion site swelling, injection site phlebitis,<br />oedema peripheral, tenderness, chest discomfort, chest pain, face oedema, feeling of body<br />temperature change, induration, infusion site extravasation, infusion site irritation, infusion site<br />phlebitis, infusion site rash, infusion site urticaria, injection site erythema, injection site<br />oedema, injection site pain, injection site swelling, malaise, oedema<br /><strong>Investigations:</strong><br />Common: blood potassium decreased, blood albumin decreased<br />Uncommon: blood creatinine increased, red blood cells urine positive, protein total decreased,<br />protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium<br />decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood<br />chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus<br />decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin<br />time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium<br />increased, blood pressure increased, blood uric acid decreased, blood urine present, breath<br />sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased,<br />international normalised ratio increased, urinary casts, white blood cells urine positive, and pH<br />urine increased.<br />Caspofungin has also been evaluated at 150 mg daily (for up to 51 days) in 100 adult patients<br />(see section 5.1). The study compared caspofungin at 50 mg daily (following a 70-mg loading<br />dose on Day 1) versus 150 mg daily in the treatment of invasive candidiasis. In this group of<br />patients, the safety of caspofungin at this higher dose appeared generally similar to patients<br />receiving the 50-mg daily dose of caspofungin. The proportion of patients with a serious drug-</p><p>related adverse reaction or a drug-related adverse reaction leading to caspofungin<br />discontinuation was comparable in the 2 treatment groups.<br /><em><u>Paediatric Patients</u></em><br />Data from 5 clinical studies completed in 171 paediatric patients suggest that the overall<br />incidence of clinical adverse experiences (26.3%; 95% CI -19.9, 33.6) is not worse than<br />reported for adults treated with caspofungin (43.1%; 95% CI -40.0, 46.2). However, paediatric<br />patients probably have a different adverse event profile compared to adult patients. The most<br />common drug-related clinical adverse experiences reported in paediatric patients treated with<br />caspofungin were pyrexia (11.7%), rash (4.7%) and headache (2.9%).<br />The following adverse reactions were reported:<br />[Very common (&ge; 1/10), Common (&ge; 1/100 to &lt;1/10)]<br /><strong>Blood and lymphatic system disorders:</strong><br />Common: eosinophil count increased<br /><strong>Nervous system disorders:</strong><br />Common: headache<br /><strong>Cardiac disorders:</strong><br />Common: tachycardia<br /><strong>Vascular disorders:</strong><br />Common: flushing, hypotension<br /><strong>Hepatobiliary disorders:</strong><br />Common: elevated liver enzyme levels (AST, ALT)<br /><strong>Skin and subcutaneous tissue disorders:</strong><br />Common: rash, pruritus<br /><strong>General disorders and administration site conditions:</strong><br />Very common: fever<br />Common: chills, catheter site pain<br /><strong>Investigations:</strong><br />Common: decreased potassium, hypomagnesaemia, increased glucose, decreased phosphorus,<br />and increased phosphorus<br /><em><u>Post-Marketing experience:</u></em><br />The following post-marketing adverse reactions have been reported:<br /><strong>Hepatobiliary disorders:</strong><br />Hepatic dysfunction, gamma-glutamyltransferase increased</p><p><strong>General disorders and administration site conditions:</strong><br />Swelling and peripheral oedema<br /><strong>Investigations:</strong><br />Hypercalcaemia<br /><em><u>Reporting of suspected adverse reactions</u></em><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important.<br />It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_8" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:61.8pt;margin-top:2.25pt;
 width:377.2pt;height:119.25pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvertent administration of up to 400 mg of caspofungin in one day has been reported. These<br />occurrences did not result in clinically important adverse reactions. Caspofungin is not<br />dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antimycotics for systemic use, ATC Code: J02AX04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of <em>Glarea lozoyensis. </em>Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.</p><p>Fungicidal activity with caspofungin has been demonstrated against <em>Candida</em> yeasts. Studies <em>in vitro</em> and <em>in vivo </em>demonstrate that exposure of <em>Aspergillus</em> to caspofungin results in lysis and death of hyphal apical tips and branch points where cell growth and division occur.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>Caspofungin has <em>in vitro</em> activity against <em>Aspergillus</em> species (<em>Aspergillus fumigatus </em>[N = 75]<em>, Aspergillus flavus </em>[N = 111]<em>, Aspergillus niger</em> [N = 31]<em>, Aspergillus nidulans </em>[N = 8]<em>, Aspergillus terreus </em>[N = 52], and <em>Aspergillus candidus </em>[N = 3]). Caspofungin also has <em>in vitro</em> activity against <em>Candida</em> species (<em>Candida albicans</em> [N = 1,032]<em>, Candida dubliniensis</em> [N = 100]<em>, Candida glabrata</em> [N = 151]<em>, Candida guilliermondii</em> [N = 67]<em>, Candida kefyr</em> [N = 62]<em>, Candida krusei</em> [N = 147]<em>, Candida lipolytica</em> [N = 20]<em>, Candida lusitaniae</em> [N = 80]<em>, Candida parapsilosis</em> [N = 215], <em>Candida rugosa</em> [N = 1], and <em>Candida tropicalis</em> [N = 258]), including isolates with multiple resistance transport mutations and those with acquired or intrinsic resistance to fluconazole, amphotericin B, and 5-flucytosine. Susceptibility testing was performed according to a modification of both the Clinical and Laboratory Standards Institute (CLSI, formerly known as the National Committee for Clinical Laboratory Standards [NCCLS]) method M38-A2 (for <em>Aspergillus</em> species) and method M27-A3 (for <em>Candida</em> species). Standardised techniques for susceptibility testing have been established for yeasts by EUCAST. However, interpretive breakpoints for caspofungin have not been approved by EUCAST.<strong> </strong>Isolates of Candida with reduced susceptibility to caspofungin have been identified in a small number of patients during treatment (MICs for caspofungin &gt;2 mg/L (4- to 30-fold MIC increases) have been reported using standardized MIC testing techniques approved by the CLSI).The mechanism of resistance identified was FKS1/FKS2 gene mutation. These cases have been associated with poor clinical outcomes. Development of <em>in vitro</em> resistance to caspofungin by <em>Aspergillus</em> species has been identified. In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed. The mechanism of resistance has not been established. The incidence of resistance to caspofungin by various clinical isolates of <em>Candida</em> and <em>Aspergillus</em> is rare.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><em>Invasive Candidiasis in Adult Patients</em>: Two hundred thirty-nine patients were enrolled in an initial study to compare caspofungin and amphotericin B for the treatment of invasive candidiasis. Twenty-four patients had neutropaenia. The most frequent diagnoses were bloodstream infections (candidaemia) (77 %, n=186) and <em>Candida </em>peritonitis (8 %, n=19); patients with <em>Candida</em> endocarditis, osteomyelitis, or meningitis were excluded from this study. Caspofungin 50 mg once daily was administered following a 70 mg loading dose, while amphotericin B was administered at 0.6 to 0.7 mg/kg/day to non-neutropaenic patients or 0.7 to 1.0 mg/kg/day to neutropaenic patients. The mean duration of intravenous therapy was 11.9 days, with a range of 1 to 28 days. A favourable response required both symptom resolution and microbiological clearance of the <em>Candida </em>infection. Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favourable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73 % [80/109]) and amphotericin B (62 % [71/115]) [% difference 12.7 (95.6 % CI -0.7, 26.0)]. Among patients with candidaemia, favourable response rates at the end of IV study therapy were comparable for caspofungin (72 % [66/92]) and amphotericin B (63 % [59/94]) in the primary efficacy analysis (MITT analysis) [% difference 10.0 (95.0 % CI -4.5, 24.5)]. Data in patients with non-blood sites of infection were more limited. Favourable response rates in neutropaenic patients were 7/14 (50 %) in the caspofungin group and 4/10 (40 %) in the amphotericin B group. These limited data are supported by the outcome of the empirical therapy study.</p><p>&nbsp;</p><p>In a second study, patients with invasive candidiasis received daily doses of caspofungin at 50 mg/day (following a 70-mg loading dose on Day 1) or caspofungin at 150 mg/day (see section 4.8). In this study, the caspofungin dose was administered over 2 hours (instead of the routine 1-hour administration). The study excluded patients with suspected <em>Candida</em> endocarditis, meningitis, or osteomyelitis. As this was a primary therapy study, patients who were refractory to prior antifungal agents were also excluded. The number of neutropenic patients enrolled in this study was also limited (8.0 %). Efficacy was a secondary endpoint in this study. Patients who met the entry criteria and received one or more doses of caspofungin study therapy were included in the efficacy analysis. The favorable overall response rates at the end of caspofungin therapy were similar in the 2 treatment groups: 72 % (73/102) and 78 % (74/95) for the caspofungin 50-mg and 150-mg treatment groups, respectively (difference 6.3 % [95 % CI -5.9, 18.4]).</p><p><em>&nbsp;</em></p><p><em>Invasive Aspergillosis in Adult Patients</em>: Sixty-nine adult patients (age 18-80) with invasive aspergillosis were enrolled in an open-label, non-comparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Patients had to be either refractory to (disease progression or failure to improve with other antifungal therapies given for at least 7 days) (84 % of the enrolled patients) or intolerant of (16 % of enrolled patients) other standard antifungal therapies. Most patients had underlying conditions (haematologic malignancy [N = 24], allogeneic bone marrow transplant or stem cell transplant [N = 18], organ transplant [N = 8], solid tumour [N = 3], or other conditions [N = 10]). Stringent definitions, modelled after the Mycoses Study Group Criteria, were used for diagnosis of invasive aspergillosis and for response to therapy (favourable response required clinically significant improvement in radiographs as well as in signs and symptoms). The mean duration of therapy was 33.7 days, with a range of 1 to 162 days. An independent expert panel determined that 41 % (26/63) of patients receiving at least one dose of caspofungin had a favourable response. For those patients who received more than 7 days of therapy with caspofungin, 50 % (26/52) had a favourable response. The favourable response rates for patients who were either refractory to or intolerant of previous therapies were 36 % (19/53) and 70 % (7/10), respectively. Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favourable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/5 versus 17/48, respectively). The response rates among patients with pulmonary disease and extrapulmonary disease were 47 % (21/45) and 28 % (5/18), respectively. Among patients with extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible CNS involvement had a favourable response.</p><p><em>&nbsp;</em></p><p><em>Empirical Therapy in Febrile, Neutropaenic Adult Patients</em>: A total of 1,111 patients with persistent fever and neutropaenia were enrolled in a clinical study and treated with either caspofungin 50 mg once daily following a 70 mg loading dose or liposomal amphotericin B 3.0 mg/kg/day. Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (&lt;500 cells/mm<sup>3</sup> for 96 hours) and fever (&gt;38.0&deg;C) not responding to &ge; 96 hours of parenteral antibacterial therapy. Patients were to be treated until up to 72 hours after resolution of neutropaenia, with a maximum duration of 28 days. However, patients found to have a documented fungal infection could be treated longer. If the drug was well tolerated but the patient&#39;s fever persisted and clinical condition deteriorated after 5 days of therapy, the dosage of study drug could be increased to 70 mg/day of caspofungin (13.3 % of patients treated) or to 5.0 mg/kg/day of liposomal amphotericin B (14.3 % of patients treated). There were 1,095 patients included in the primary Modified Intention-To-Treat (MITT) efficacy analysis of overall favourable response; caspofungin (33.9 %) was as effective as liposomal amphotericin B (33.7 %) [% difference 0.2 (95.2 % CI &ndash;5.6, 6.0)]. An overall favourable response required meeting each of 5 criteria: (1) successful treatment of any baseline fungal infection (caspofungin 51.9 % [14/27], liposomal amphotericin B 25.9 % [7/27]), (2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment (caspofungin 94.8 % [527/556], liposomal amphotericin B 95.5 % [515/539]), (3) survival for 7 days after completion of study therapy (caspofungin 92.6 % [515/556], liposomal amphotericin B 89.2 % [481/539]), (4) no discontinuation from the study drug because of drug-related toxicity or lack of efficacy (caspofungin 89.7 % [499/556], liposomal amphotericin B 85.5 % [461/539]), and (5) resolution of fever during the period of neutropaenia (caspofungin 41.2 % [229/556], liposomal amphotericin B 41.4 % [223/539]). Response rates to caspofungin and liposomal amphotericin B for baseline infections caused by <em>Aspergillus</em> species were, respectively, 41.7 % (5/12) and 8.3 % (1/12), and by <em>Candida</em> species were 66.7 % (8/12) and 41.7 % (5/12). Patients in the caspofungin group experienced breakthrough infections due to the following uncommon yeasts and moulds: <em>Trichosporon</em> species (1), <em>Fusarium</em> species (1), <em>Mucor</em> species (1), and <em>Rhizopus</em> species (1).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The safety and efficacy of caspofungin was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials. The study design, diagnostic criteria, and criteria for efficacy assessment were similar to the corresponding studies in adult patients (see section 5.1)<em>.</em></p><p>&nbsp;</p><p>The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, double-blind study comparing caspofungin (50 mg/m<sup>2 </sup>IV once daily following a 70-mg/m<sup>2</sup> loading dose on Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in paediatric patients with persistent fever and neutropenia. The overall success rates in the MITT analysis results, adjusted by risk strata, were as follows: 46.6 % (26/56) for caspofungin and 32.2 % (8/25) for liposomal amphotericin B.</p><p>&nbsp;</p><p>The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in paediatric patients (ages 6 months to 17 years) with invasive candidiasis, esophageal candidiasis, and invasive aspergillosis (as salvage therapy). Forty-nine patients were enrolled and received caspofungin at 50 mg/m<sup>2 </sup>IV once daily following a 70-mg/m<sup>2</sup> loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis. Of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis. The favorable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81 % (30/37) in invasive candidiasis, 50 % (5/10) in invasive aspergillosis, and 100 % (1/1) in esophageal candidiasis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>Caspofungin is extensively bound to albumin. The unbound fraction of caspofungin in plasma varies from 3.5 % in healthy volunteers to 7.6 % in patients with invasive candidiasis. Distribution plays the prominent role in caspofungin plasma pharmacokinetics and is the rate-controlling step in both the alpha- and beta-disposition phases. The distribution into tissues peaked at 1.5 to 2 days after dosing when 92 % of the dose was distributed into tissues. It is likely that only a small fraction of the caspofungin taken up into tissues later returns to plasma as parent compound. Therefore, elimination occurs in the absence of a distribution equilibrium, and a true estimate of the volume of distribution of caspofungin is currently impossible to obtain.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>Caspofungin undergoes spontaneous degradation to an open ring compound. Further metabolism involves peptide hydrolysis and N-acetylation. Two intermediate products, formed during the degradation of caspofungin to this open ring compound, form covalent adducts to plasma proteins resulting in a low-level, irreversible binding to plasma proteins.</p><p><em>In vitro</em> studies show that caspofungin is not an inhibitor of cytochrome P450 enzymes 1A2, 2A6, 2C9, 2C19, 2D6 or 3A4. In clinical studies, caspofungin did not induce or inhibit the CYP3A4 metabolism of other medicinal products. Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The elimination of caspofungin from plasma is slow with a clearance of 10-12 ml/min. Plasma concentrations of caspofungin decline in a polyphasic manner following single 1-hour intravenous infusions. A short alpha-phase occurs immediately post-infusion, followed by a beta-phase with a half-life of 9 to 11 hours. An additional gamma-phase also occurs with a half-life of 45 hours. Distribution, rather than excretion or biotransformation, is the dominant mechanism influencing plasma clearance.</p><p>Approximately 75 % of a radioactive dose was recovered during 27 days: 41 % in urine and 34 % in faeces. There is little excretion or biotransformation of caspofungin during the first 30 hours after administration. Excretion is slow and the terminal half-life of radioactivity was 12 to 15 days. A small amount of caspofungin is excreted unchanged in urine (approximately 1.4 % of dose).</p><p>&nbsp;</p><p>Caspofungin displays moderate non-linear pharmacokinetics with increased accumulation as the dose is increased, and a dose dependency in the time to reach steady state upon multiple-dose administration.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>Increased caspofungin exposure was seen in adult patients with renal impairment and mild liver impairment, in female subjects, and in the elderly. Generally the increase was modest and not large enough to warrant dosage adjustment. In adult patients with moderate liver impairment or in higher weight patients, a dosage adjustment may be necessary (see below).</p><p>Weight: Weight was found to influence caspofungin pharmacokinetics in the population pharmacokinetic analysis in adult candidiasis patients. The plasma concentrations decrease with increasing weight. The average exposure in an adult patient weighing 80 kg was predicted to be about 23 % lower than in an adult patient weighing 60 kg (see section 4.2).</p><p>Hepatic impairment: In adult patients with mild and moderate hepatic impairment, the AUC is increased about 20 and 75 %, respectively. There is no clinical experience in adult patients with severe hepatic impairment and in paediatric patients with any degree of hepatic impairment. In a multiple-dose study, a dose reduction of the daily dose to 35 mg in adult patients with moderate hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen (see section 4.2).</p><p>&nbsp;</p><p>Renal impairment: In a clinical study of single 70 mg doses, caspofungin pharmacokinetics were similar in adult volunteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and control subjects. Moderate (creatinine clearance 31 to 49 ml/min), advanced (creatinine clearance 5 to 30 ml/min), and end-stage (creatinine clearance &lt;10 ml/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49 % for AUC). However, in adult patients with invasive candidiasis, oesophageal candidiasis, or invasive aspergillosis who received multiple daily doses of caspofungin 50 mg, there was no significant effect of mild to advanced renal impairment on caspofungin concentrations. No dosage adjustment is necessary for patients with renal impairment. Caspofungin is not dialysable, thus supplementary dosing is not required following haemodialysis.</p><p>Gender: Caspofungin plasma concentrations were on average 17-38 % higher in women than in men.</p><p>&nbsp;</p><p>Elderly: A modest increase in AUC (28 %) and C<sub>24h</sub> (32 %) was observed in elderly male subjects compared with young male subjects. In patients who were treated empirically or who had invasive candidiasis, a similar modest effect of age was seen in older patients relative to younger patients.</p><p>&nbsp;</p><p>Race: Patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and Mestizos.</p><p>&nbsp;</p><p>Paediatric Patients:</p><p>In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg/m<sup>2</sup> daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub> was generally comparable to that seen in adults receiving caspofungin at 50 mg daily. All adolescents received doses &gt;50 mg daily, and, in fact, 6 of 8 received the maximum dose of 70 mg/day. The caspofungin plasma concentrations in these adolescents were reduced relative to adults receiving 70 mg daily, the dose most often administered to adolescents.</p><p>&nbsp;</p><p>In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m<sup>2</sup> daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub> after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg/day.</p><p>&nbsp;</p><p>In young children and toddlers (ages 12 to 23 months) receiving caspofungin at 50 mg/m<sup>2</sup> daily (maximum 70 mg daily), the caspofungin plasma AUC<sub>0-24hr</sub> after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily and to that in older children (2 to 11 years of age) receiving the 50 mg/m<sup>2</sup> daily dose.</p><p>&nbsp;</p><p>Overall, the available pharmacokinetic, efficacy, and safety data are limited in patients 3 to 10 months of age. Pharmacokinetic data from one 10-month old child receiving the 50 mg/m<sup>2</sup> daily dose indicated an AUC<sub>0-24hr</sub> within the same range as that observed in older children and adults at the 50 mg/m<sup>2</sup> and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m<sup>2</sup> dose, the AUC<sub>0-24hr</sub> was somewhat higher.</p><p>&nbsp;</p><p>In neonates and infants (&lt;3 months) receiving caspofungin at 25 mg/m<sup>2</sup> daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C<sub>1 hr</sub>) and caspofungin trough concentration (C<sub>24 hr</sub>) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily. On Day 1, C<sub>1 hr</sub> was comparable and C<sub>24 hr</sub> modestly elevated (36 %) in these neonates and infants relative to adults. However, variability was seen in both C<sub>1 hr</sub> (Day 4 geometric mean 11.73 &micro;g/ml, range 2.63 to 22.05 &micro;g/ml) and C<sub>24 hr</sub> (Day 4 geometric mean 3.55 &micro;g/ml, range 0.13 to 7.17 &micro;g/ml). AUC<sub>0-24hr</sub> measurements were not performed in this study due to the sparse plasma sampling. Of note, the efficacy and safety of caspofungin have not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated dose toxicity studies in rats and monkeys using doses up to 7-8 mg/kg given<br />intravenously showed injection site reactions in rats and monkeys, signs of histamine release in<br />rats, and evidence of adverse effects directed at the liver in monkeys. Developmental toxicity<br />studies in rats showed that caspofungin caused decreases in foetal body weights and an<br />increase in the incidence of incomplete ossification of vertebra, sternebra, and skull bone at<br />doses of 5 mg/kg that were coupled to adverse maternal effects such as signs of histamine<br />release in pregnant rats. An increase in the incidence of cervical ribs was also noted.<br />Caspofungin was negative in in vitro assays for potential genotoxicity as well as in the in vivo<br />mouse bone marrow chromosomal test. No long-term studies in animals have been performed<br />to evaluate the carcinogenic potential. For caspofungin, there were no effects on fertility in<br />studies conducted in male and female rats up to 5 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Mannitol<br />Glacial acetic acid<br />Sodium hydroxide (to adjust the pH)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not mix with diluents containing glucose, as Fungiska is not stable in diluents containing<br />glucose. In the absence of compatibility studies, this medicinal product must not be mixed with<br />other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Fungiska 50 mg: 24 months
For Fungiska 70 mg: 24 months
Fungiska contains no preservatives. From a microbiological point of view, the product should
be used immediately. If not used immediately, in use storage times and conditions prior to use
are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C or
below 25°C, unless reconstitution and dilution have taken place in controlled validated aseptic
conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unopened vials: store in a refrigerator (2&deg;C - 8&deg;C).<br />For storage conditions after reconstitution and dilution of the medicinal product, see section<br />6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml Type I glass vial with a rubber stopper and an aluminium flip-off cap.<br />Supplied in packs of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reconstitution of Fungiska</u></p><p>DO NOT USE ANY DILUENTS CONTAINING GLUCOSE, as Fungiska is not stable in diluents containing glucose. DO NOT MIX OR CO-INFUSE Fungiska WITH ANY OTHER MEDICINES, as there are no data available on the compatibility of Fungiska with other intravenous substances, additives, or medicinal products. Visually inspect the infusion solution for particulate matter or discolouration.</p><p><strong>&nbsp;</strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>INSTRUCTIONS FOR USE IN ADULT PATIENTS</strong></p><p><strong>Step 1 Reconstitution of conventional vials </strong></p><p>To reconstitute the 50 mg powder, bring the vial to room temperature and aseptically add 10.5 ml of water for injection. The concentrations of the reconstituted vials will be 5.2 mg/ml.</p><p>&nbsp;</p><p>To reconstitute the 70 mg powder, bring the vial to room temperature and aseptically add 10.5 ml of water for injection. The concentrations of the reconstituted vials will be 7.2 mg/ml.</p><p>&nbsp;</p><p>The white to off-white compact lyophilised powder will dissolve completely. Mix gently until a clear solution is obtained. Reconstituted solutions should be visually inspected for particulate matter or discolouration. This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.</p><p><strong>&nbsp;</strong></p><p><strong>Step 2 Addition of reconstituted Fungiska to patient infusion solution </strong></p><p>Diluents for the final solution for infusion are: sodium chloride solution for injection, or lactated Ringer&rsquo;s solution. The solution for infusion is prepared by aseptically adding the appropriate amount of reconstituted concentrate (as shown in the table below) to a 250 ml infusion bag or bottle. Reduced volume infusions in 100 ml may be used, when medically necessary, for 50 mg or 35 mg daily doses.</p><p>Do not use if the solution is cloudy or has precipitated.</p><p>&nbsp;</p><p><strong>PREPARATION OF THE SOLUTION FOR INFUSION IN ADULTS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>DOSE*</strong></p></td><td style="vertical-align:top"><p><strong>Volume of reconstituted Fungiska for transfer to intravenous bag or bottle</strong></p></td><td style="vertical-align:top"><p><strong>Standard preparation</strong></p><p>(reconstituted Fungiska added to 250 ml) final concentration</p></td><td style="vertical-align:top"><p><strong>Reduced volume</strong></p><p><strong>infusion</strong></p><p>(reconstituted</p><p>Fungiska added to 100 ml) final concentration</p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>0.20 mg/ml</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>50 mg at reduced</p><p>volume</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.47 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>35 mg for moderate</p><p>hepatic impairment</p><p>(from one 50 mg vial)</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>0.14 mg/ml</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>35 mg for moderate</p><p>hepatic impairment</p><p>(from one 50 mg vial) at reduced volume</p></td><td style="vertical-align:top"><p>7 ml</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>0.34 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>70 mg</p></td><td style="vertical-align:top"><p>10 ml</p></td><td style="vertical-align:top"><p>0.28 mg/ml</p></td><td style="vertical-align:top"><p>Not Recommended</p></td></tr><tr><td style="vertical-align:top"><p>70 mg (from two 50-mg</p><p>vials)**</p></td><td style="vertical-align:top"><p>14 ml</p></td><td style="vertical-align:top"><p>0.28 mg/ml</p></td><td style="vertical-align:top"><p>Not Recommended</p></td></tr><tr><td style="vertical-align:top"><p>35 mg for moderate</p><p>hepatic impairment</p><p>(from one 70 mg vial)</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>0.14 mg/ml</p></td><td style="vertical-align:top"><p>0.34 mg/ml</p></td></tr></tbody></table><p><strong>*</strong> 10.5 ml should be used for reconstitution of all vials.</p><p><strong>**</strong><strong> </strong>If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials.</p><p><strong>&nbsp;</strong></p><p><strong>INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS</strong></p><p><em><u>Calculation of Body Surface Area (BSA) for paediatric dosing</u></em></p><p>Before preparation of infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller Formula)</p><p><img src="data:image/jpeg;base64,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" alt="" width="292" height="70" vspace="0" hspace="0" border="0" style="width:292px;height:70px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong><em><u>Preparation of the 70 mg/m<sup>2 </sup>infusion for paediatric patients &gt;3 months of age (using a 50-mg vial)</u></em></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the actual loading dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 70 mg/m<sup>2</sup> = Loading Dose</p><p>The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equilibrate the refrigerated vial of Fungiska to room temperature.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptically add 10.5 ml of water for injection.<sup>a</sup> This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup> This will give a final caspofungin concentration in the vial of 5.2 mg/ml.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the volume of medicinal product equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup> of reconstituted Fungiska to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>c</sup> of reconstituted Fungiska can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at 2 to 8&deg;C or below 25&deg;C.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Preparation of the 50 mg/m<sup>2 </sup>infusion for paediatric patients &gt;3 months of age (using a 50-mg vial)</u></em></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 50 mg/m<sup>2</sup> = Daily Maintenance Dose</p><p>The daily maintenance dose should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equilibrate the refrigerated vial of Fungiska to room temperature.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptically add 10.5 ml of water for injection.<sup>a</sup> This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b </sup>This will give a final caspofungin concentration in the vial of 5.2 mg/ml.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the volume of medicinal product equal to the calculated daily maintenance dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>c</sup> of reconstituted Fungiska to an IV bag (or bottle) containing 250 ml of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>c</sup> of reconstituted Fungiska can be added to a reduced volume of 0.9%, 0.45%, or 0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at 2 to 8&deg;C or below 25&deg;C.</p><p>&nbsp;</p><p><strong><em><u>Preparation of the 70 mg/m2 infusion for paediatric patients &gt;3 months of age (using a 70-mg vial)</u></em></strong></p><p>1. Determine the actual loading dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 70 mg/m<sup>2</sup> = Loading Dose</p><p>The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Fungiska to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.<sup>a </sup>This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup> This will give a final caspofungin concentration in the vial of 7.2 mg/ml.</p><p>4. Remove the volume of medicine equal to the calculated loading dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>d</sup> of reconstituted Fungiska to an IV bag (or bottle) containing 250 ml of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>d </sup>of reconstituted Fungiska can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at 2 to 8&deg;C or below 25&deg;C.</p><p>&nbsp;</p><p><strong><em><u>Preparation of the 50 mg/m2 infusion for paediatric patients &gt;3 months of age (using a 70-mg vial)</u></em></strong></p><p>1. Determine the actual daily maintenance dose to be used in the paediatric patient by using the patient&#39;s BSA (as calculated above) and the following equation:</p><p>BSA (m<sup>2</sup>) X 50 mg/m<sup>2</sup> = Daily Maintenance Dose</p><p>The daily maintenance dose should not exceed 70 mg regardless of the patient&#39;s calculated dose.</p><p>2. Equilibrate the refrigerated vial of Fungiska to room temperature.</p><p>3. Aseptically add 10.5 ml of water for injection.<sup>a</sup> This reconstituted solution may be stored for up to 24 hours at or below 25&deg;C.<sup>b</sup> This will give a final caspofungin concentration in the vial of 7.2 mg/ml.</p><p>4. Remove the volume of medicine equal to the calculated daily maintenance dose (Step 1) from the vial. Aseptically transfer this volume (ml)<sup>d </sup>of reconstituted Fungiska to an IV bag (or bottle) containing 250 ml of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection, or Lactated Ringers Injection. Alternatively, the volume (ml)<sup>d </sup>of reconstituted Fungiska can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a final concentration of 0.5 mg/ml. This infusion solution must be used within 24 hours if stored at 2 to 8&deg;C or below 25&deg;C.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Preparation notes:</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>a </strong>The white to off-white cake will dissolve completely. Mix gently until a clear solution is obtained.</p><p><strong>b </strong>Visually inspect the reconstituted solution for particulate matter or discoloration during</p><p>reconstitution and prior to infusion. Do not use if the solution is cloudy or has precipitated.<strong> </strong></p><p><strong>c </strong>Fungiska is formulated to provide the full labeled vial dose (50 mg) when 10 ml is withdrawn from the vial.</p><p><strong>d </strong>Fungiska is formulated to provide the full labeled vial dose (70 mg) when 10 ml is withdrawn from the vial.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by
MEFAR İLAÇ SANAYİİ A.Ş. Turkey
For
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Pharmaceutical Industries &
Medical Appliances Corporation
Saudi Arabia


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>